NEW: Monkeypox & Vaccinia Peptide Pools & Microarrays!
Published on 06/07/2022
With the recent emergence of a new monkeypox strain, questions about its severity and potential spread among humans remain to be answered. There are indications that the smallpox vaccine also leads to increased immunity against the monkeypox virus. This is in line with the observation that some antigens show a high homology within different viruses of the poxvirus family.
See our monkeypox page for further details.
To study cross immunity and monitor immune cell activity, our R&D Team developed a new:
containing 127 immunodominant peptide epitopes combining all major antigens of
- Monkeypox virus (MPXV)
- Vaccinia virus (VACV)
- Variola virus (VARV, smallpox)
In addition, we offer a variety of antigen-specific vaccinia PepMix Peptide Pools such as
- PepMix Vaccinia virus (L3L)
- PepMix Vaccinia virus (MVA018L)
- PepMix Vaccinia virus (MVA074R)
- PepMix Vaccinia virus (MVA093L)
- PepMix Vaccinia virus (MVA105L)
- PepMix Vaccinia virus (MVA121L)
- PepMix Vaccinia virus (MVA189R)
as well as different PepStar Peptide Microarrays that cover various surface proteins including common mutations to study epitope resolved antibody responses directed against these antigens.
Please contact us if you want to share any comments or have questions or you require a Custom Peptide Synthesis tailored to your needs!